SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-150838
Filing Date
2021-12-17
Accepted
2021-12-17 07:12:30
Documents
14
Period of Report
2021-12-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2135684d2_8k.htm   iXBRL 8-K 27863
2 EXHIBIT 99.1 tm2135684d2_ex99-1.htm EX-99.1 10347
6 GRAPHIC tm2135684d2_ex99-1img001.jpg GRAPHIC 8923
  Complete submission text file 0001104659-21-150838.txt   227017

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA casi-20211217.xsd EX-101.SCH 3025
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE casi-20211217_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE casi-20211217_pre.xml EX-101.PRE 22359
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2135684d2_8k_htm.xml XML 3584
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

IRS No.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-20713 | Film No.: 211499484
SIC: 2836 Biological Products, (No Diagnostic Substances)